MedX Announces Extension of Non-Brokered Private Placement
MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, when it announced the Initial Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025, it has made application to the TSX Venture Exchange for an extension of 30 days to June 6, 2025, within which to effect further closings on this Private Placement. The Initial Closing, effective April 3, 2025, comprised the issuance of 13,500,000 Units (as described in detail in the Company's Press Release dated April 7, 2025) and raised cash proceeds of $945,000. With the extension of the final date for this Placement, it is anticipated that further Closings will take place, for up to a maximum of a further 22,214,285 Units at $0.07 per Unit, to raise up to a further $1,555,000. As previously announced, it is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Funds raised in this Placement will be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
The Stock Market Is Rising — and These Hidden Gems Are Staying Cheap
Written by Sneha Nahata at The Motley Fool Canada The S&P/TSX Composite Index, also regarded as the benchmark for the Canadian stock market, has been rising amid easing concerns about a macroeconomic slowdown and interest rate cuts. While many stocks on the TSX have surged, several hidden gems continue to trade at attractive valuations, presenting a compelling opportunity for investors to consider. Against this backdrop, here are a few hidden gems that remain cheap and have solid growth potential. goeasy (TSX:GSY) is one of the top TSX stocks to buy now for its attractive valuation. Despite its impressive track record of solid growth and strong fundamentals, the market is undervaluing this Canadian financial services company. Currently, its shares trade at a next 12-month price-to-earnings (P/E) multiple of around eight, a level that suggests it could be a hidden gem, especially when you consider its potential for sustained earnings growth in the double digits. goeasy operates in the subprime lending space and has proven its ability to thrive in this niche. Over the past five years, the company's sales have grown at a compound annual growth rate (CAGR) of more than 19%. Moreover, its earnings have increased at a CAGR of nearly 26%, outpacing revenue growth. That upward momentum has been reflected in its stock price, which has surged more than 212% over the last five years. Moreover, its solid profitability has driven a consistent increase in its dividend. goeasy has paid a dividend every year for the past 21 years and has increased it for 11 consecutive years, making it a dependable income stock. goeasy's dominance in Canada's subprime lending market, expansion of its consumer loan portfolio, diversified funding sources, and solid underwriting practices position it well to scale rapidly while maintaining profitability. In summary, goeasy offers a compelling mix of value, growth, and income. Its low valuation, strong earnings trajectory, and consistent shareholder returns make it a top pick for creating wealth. Investors seeking a high-quality stock with an attractive valuation could consider WELL Health Technologies (TSX:WELL). This digital healthcare company has been performing well, led by steady demand for its omnichannel patient care services. Moreover, its strategic acquisitions have accelerated its growth and broadened its footprint. Despite its solid operational performance, WELL Health's stock appears significantly undervalued. Currently, it trades at a near-historical low NTM enterprise value-to-sales ratio of just one. This discounted valuation presents a compelling opportunity for investors. WELL Health's growth story shows no signs of slowing down. Besides organic growth, WELL Health will benefit from its acquisitions. The company recently acquired a stake in HEALWELL AI, which will enhance its scale. Moreover, it remains focused on expanding its footprint in Canada, particularly in its patient care and technology services segments. Operationally, WELL Health continues to streamline operations to improve profitability. Moreover, it is strengthening its financial position by reducing debt. Furthermore, WELL Health's focus on minimizing share dilution is a positive aspect. Given its solid growth, improving fundamentals, and attractively low valuation, WELL Health Technologies offers a combination of growth and value. The post The Stock Market Is Rising — and These Hidden Gems Are Staying Cheap appeared first on The Motley Fool Canada. Before you buy stock in goeasy, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and goeasy wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $21,345.77!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*. See the Top Stocks * Returns as of 4/21/25 More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Sneha Nahata has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
2 TSX Value Stocks to Buy When Everyone Else Is Selling
Written by Adam Othman at The Motley Fool Canada There is always value to be found in the stock market, even when the broader market has a bullish trend. As of this writing, the S&P/TSX Composite Index, which is the benchmark for the Canadian stock market, is nearing new all-time highs. The index is up by almost 17% from its low on April 8, 2025. Typically, savvier investors who can see through the noise of a market sell-off focus on investing when everyone else sells. What if I told you those investors still have opportunities to buy undervalued stocks even when the market is hitting new all-time highs? Year to date, the TSX is up by 5.75%. However, the TSX still has plenty of stocks trailing behind the rest of the market. Today, I will discuss two of them to help you determine whether they might be good candidates to consider long-term winners or stocks to avoid like the plague in your self-directed portfolio. Air Canada (TSX:AC) is a battered and bruised giant in the Canadian airline industry. The $6.05 billion market-cap company is Canada's flag-bearing and largest airline. The company operates domestic, U.S.-Canada transborder flights and several international routes worldwide. Air Canada was one of the top 20 largest airlines worldwide before COVID struck in 2019. Since the pandemic, the stock has failed to recover to better valuations. Despite not operating any flights, AC stock faced considerable cash burn to maintain its fleet, resulting in massive debt for the company without a recovery through operational revenue. Air Canada's most recent earnings report for the first quarter of 2025 saw it report $5.2 billion in revenue. Slightly down from $5.23 billion in the same quarter last year, the airline still generated around $387 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). The company continues to expand its capacity, and while it may take a long time, there seems to be a recovery on the horizon. Suncor Energy (TSX:SU) is another battered stock but in an entirely different industry. The $61.02 billion market-cap firm based in Calgary is an integrated energy company. It has operations that include oil sands development, production and upgrading, petroleum refining, offshore oil and gas operations, and wholesale distribution networks to retail the end product directly to consumers. The company is also advancing its transition into a lower-emission future. The company trades at roughly 10.29 times trailing earnings, indicating that it might be undervalued right now. As of this writing, Suncor stock trades for $49.71 per share and distributes $0.57 per share each quarter to its shareholders, reflecting a 4.59% annualized dividend yield. It can be a good investment to consider for locking in high-yielding dividends and long-term capital gains. For most investors, investing when the market is going downward does not make sense. Why invest in a bear market when there's nothing but losses everywhere? Smarter investors know how to use those downturns as opportunities to invest in undervalued stocks at a bargain. Despite what some investors might think, there still are opportunities during upticks to invest in bargains. Suncor stock and Air Canada stock might seem very risky investments, and that's because they are. However, the potential to recover to better valuations in the long run is there. If you have a well-balanced portfolio and a higher risk tolerance, these two might be good bets to pay off a few years down the line. The post 2 TSX Value Stocks to Buy When Everyone Else Is Selling appeared first on The Motley Fool Canada. Before you buy stock in Air Canada, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Air Canada wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $21,345.77!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*. See the Top Stocks * Returns as of 4/21/25 More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
a day ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
